# AgomAb Therapeutics NV: overview

AGMB · Nasdaq · CIK 2020932 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/agmb.md) · [Financials](/companies/agmb/financials.md) · [Filings](/companies/agmb/filings.md) · [Insiders](/companies/agmb/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

Not reported.

## Last five fiscal years

Not reported.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/agmb/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [EQT Fund Management S.a r.l.](/funds/1834239.md) | 2026-06-30 | $66.7m | 5,141,992 |  | Unchanged |
| [Sanofi](/funds/1121404.md) | 2026-06-30 | $36.1m | 2,783,096 |  | Unchanged |
| [Redmile Group, LLC](/funds/1425738.md) | 2026-06-30 | $35.5m | 2,733,926 |  | Added +2,577,676 |
| [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $32.0m | 2,465,348 |  | Unchanged |
| [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $26.7m | 2,053,233 |  | Unchanged |
| [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $21.0m | 1,618,000 |  | Unchanged |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $20.4m | 1,568,188 |  | Added +368,188 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $20.4m | 1,568,188 |  | Added +368,188 |
| [Casdin Capital, LLC](/funds/1534261.md) | 2026-06-30 | $20.1m | 1,550,000 |  | Unchanged |
| [ANDERA PARTNERS](/funds/1757283.md) | 2026-06-30 | $20.0m | 1,538,702 |  | Unchanged |

## Recent filings

[All 47 filings](/companies/agmb/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-13 | 21:18 ET | [6-K](/filings/0001104659-26-115567.md) | Report of a foreign private issuer, period 2026-10-13 | 0001104659-26-115567 |
| 2026-10-01 | 10:42 ET | [6-K](/filings/0001104659-26-112564.md) | Report of a foreign private issuer, period 2026-10-01 | 0001104659-26-112564 |
| 2026-09-14 | 20:14 ET | [6-K](/filings/0001104659-26-107500.md) | Report of a foreign private issuer, period 2026-09-14 | 0001104659-26-107500 |
| 2026-09-11 | 21:02 ET | [6-K](/filings/0001104659-26-107117.md) | Report of a foreign private issuer, period 2026-09-11 | 0001104659-26-107117 |
| 2026-08-10 | 20:17 ET | [6-K](/filings/0001104659-26-093390.md) | Report of a foreign private issuer, period 2026-08-10 | 0001104659-26-093390 |
| 2026-08-06 | 20:06 ET | [6-K](/filings/0001104659-26-091992.md) | Report of a foreign private issuer, period 2026-08-06 | 0001104659-26-091992 |
| 2026-06-23 | 20:13 ET | [6-K](/filings/0001104659-26-076819.md) | Report of a foreign private issuer, period 2026-06-23 | 0001104659-26-076819 |
| 2026-05-27 | 11:12 ET | [6-K](/filings/0001104659-26-066590.md) | Report of a foreign private issuer, period 2026-05-27 | 0001104659-26-066590 |
| 2026-04-24 | 20:22 ET | [6-K](/filings/0001104659-26-048615.md) | Report of a foreign private issuer, period 2026-04-24 | 0001104659-26-048615 |
| 2026-04-23 | 21:17 ET | [20-F](/filings/0001104659-26-047872.md) | Annual report of a foreign private issuer, period 2025-12-31 | 0001104659-26-047872 |

## Latest annual report

[Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-047872.md), filed Apr 23, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 2020932
- Tickers: AGMB
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: C9
- Filer category: Non-accelerated filer<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.